Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Operating Leases (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Operating Leases for 7 consecutive years, with $10.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 7.5% year-over-year to $10.3 million, compared with a TTM value of $10.3 million through Dec 2025, down 7.5%, and an annual FY2025 reading of $10.3 million, down 7.5% over the prior year.
  • Operating Leases was $10.3 million for Q4 2025 at aTYR PHARMA, down from $10.5 million in the prior quarter.
  • Across five years, Operating Leases topped out at $12.8 million in Q2 2023 and bottomed at $133000.0 in Q1 2022.
  • Average Operating Leases over 5 years is $8.3 million, with a median of $10.7 million recorded in 2025.
  • The sharpest move saw Operating Leases plummeted 88.38% in 2022, then skyrocketed 8859.4% in 2023.
  • Year by year, Operating Leases stood at $398000.0 in 2021, then surged by 2320.35% to $9.6 million in 2022, then rose by 28.09% to $12.3 million in 2023, then decreased by 9.68% to $11.1 million in 2024, then dropped by 7.5% to $10.3 million in 2025.
  • Business Quant data shows Operating Leases for ATYR at $10.3 million in Q4 2025, $10.5 million in Q3 2025, and $10.7 million in Q2 2025.